| PRECLINICAL | evidence | In brief: GI effects of GLP-1 receptor agonists. | Ozempic | Glycemic control | 2023-11-27 |
| PRECLINICAL | evidence | Do not forget diet and exercise during Ramadan. | Ozempic | — | 2023-11-06 |
| PRECLINICAL | evidence | UK regulator warns public after seizing hundreds of fake Ozempic pens. | Ozempic | — | 2023-10-27 |
| PRECLINICAL | evidence | GLP-1 Receptor Agonists and Related Mental Health Issues; Insights from a Range of Social Media Platforms Using a Mixed-Methods Approach. | Ozempic | — | 2023-10-24 |
| PRECLINICAL | evidence | Peri-operative management of Ozempic and other GLP-1 agonists during cosmetic surgery: What plastic surgeons need to know. | Ozempic | — | 2023-10-13 |
| PRECLINICAL | evidence | A narrative review of approved and emerging anti-obesity medications. | Wegovy | — | 2023-10-01 |
| PRECLINICAL | evidence | Weight-loss drug lowers cardiovascular disease risk in new trial of Novo Nordisk's Wegovy. | Wegovy | — | 2023-10-01 |
| PRECLINICAL | evidence | This octopus-inspired patch could deliver drugs like Ozempic through your cheek. | Ozempic | — | 2023-09-27 |
| PRECLINICAL | evidence | What Is Best for Weight Loss? A Comparative Review of the Safety and Efficacy of Bariatric Surgery Versus Glucagon-Like Peptide-1 Analogue. | Ozempic | — | 2023-09-01 |
| PRECLINICAL | evidence | Daily briefing: Blockbuster anti-obesity drug Wegovy slashes heart-attack risk. | Wegovy | — | 2023-08-11 |
| PRECLINICAL | evidence | Knowledge and Attitude of the General Population in Saudi Arabia Toward Weight Management Medications (WMMs): A Cross-Sectional Study. | Ozempic | — | 2023-08-01 |
| PRECLINICAL | evidence | Beyond Ozempic: brand-new obesity drugs will be cheaper and more effective. | Ozempic | Weight & fat loss | 2023-07-01 |
| PRECLINICAL | evidence | Glucagon-like peptide 1(GLP-1) receptor agonists in the management of the patient with type 2diabetes mellitus and chronic kidney disease: an approach for the nephrologist. | semaglutida | Glycemic control | 2023-07-01 |
| PRECLINICAL | evidence | Wegovy: Weight loss drug to be available from GPs in pilot scheme. | Wegovy | Weight & fat loss | 2023-06-08 |
| PRECLINICAL | evidence | New Indication for Weight Loss Drug Semaglutide. | Wegovy | Glycemic control | 2023-06-01 |
| PRECLINICAL | evidence | Ozempic face: A new challenge for facial plastic surgeons. | Ozempic | — | 2023-06-01 |
| PRECLINICAL | evidence | First Reported Case of Dulaglutide-Induced Acute Pancreatitis With Normal Serum Lipase Level. | Ozempic | — | 2023-06-01 |
| PRECLINICAL | evidence | As Ozempic's Popularity Soars, Here's What to Know About Semaglutide and Weight Loss. | Ozempic | Weight & fat loss | 2023-05-16 |
| PRECLINICAL | evidence | [Not Available]. | Rybelsus | — | 2023-04-24 |
| PRECLINICAL | evidence | Effect of semaglutide on fatty liver disease biomarkers in patients with diabetes and obesity. | semaglutida | Glycemic control | 2023-03-01 |
| PRECLINICAL | evidence | In brief: Semaglutide (Wegovy) for weight loss in children. | Wegovy | Weight & fat loss | 2023-02-20 |
| PRECLINICAL | evidence | A Peptide in a Pill - Oral Semaglutide in the Management of Type 2 Diabetes. | Rybelsus | — | 2023-01-01 |
| PRECLINICAL | evidence | Enteroendocrine cell regulation of the gut-brain axis. | Ozempic | — | 2023-01-01 |
| PRECLINICAL | evidence | Semaglutide (Wegovy) for the Treatment of Obesity. | Wegovy | Glycemic control | 2023-01-01 |
| PRECLINICAL | evidence | Gastrointestinal Permeation Enhancers for the Development of Oral Peptide Pharmaceuticals. | Rybelsus | — | 2022-12-19 |
| PRECLINICAL | evidence | Virilization caused by ovarian nodular hyperthecosis in a postmenopausal woman. | Rybelsus | — | 2022-12-12 |
| PRECLINICAL | evidence | | Wegovy | — | 2022-12-01 |
| PRECLINICAL | evidence | Treating type 2 diabetes: moving towards precision medicine. | Rybelsus | Glycemic control | 2022-12-01 |
| PRECLINICAL | evidence | Drugs for type 2 diabetes. | Ozempic | Glycemic control | 2022-11-14 |
| PRECLINICAL | evidence | Efficacy and Safety of Semaglutide, a Glucagon-Like Peptide-1 Receptor Agonist in Real-Life: A Case Series of Patients in Maintenance Incremental Hemodialysis. | Ozempic | — | 2022-09-01 |
| PRECLINICAL | evidence | Semaglutide versus GLP-1 agonists. Effectiveness, safety, and quality of life in patients with diabetes mellitus 2. The SEVERAL study. | semaglutida | Glycemic control · n = 360 | 2022-08-30 |
| PRECLINICAL | evidence | Once-weekly 2.4 mg Semaglutide for Weight Management in Obesity: A Game Changer? | Wegovy | — | 2022-06-01 |
| PRECLINICAL | evidence | Comparison table: Some FDA-approved drugs for weight management. | Wegovy | — | 2022-05-30 |
| PRECLINICAL | evidence | Drugs and devices for weight management. | Wegovy | — | 2022-05-30 |
| PRECLINICAL | evidence | In brief: Higher-dose semaglutide (Ozempic) for type 2 diabetes. | Ozempic | Glycemic control | 2022-05-16 |
| PRECLINICAL | evidence | Acute gastric dilation associated with the use of semaglutide, a GLP-1 analogue. | semaglutida | Glycemic control | 2022-04-01 |
| PRECLINICAL | evidence | Oral semaglutide in type 2 diabetes mellitus: Comprehensive review, critical appraisal and clinical consideration of its use in India. | Rybelsus | Glycemic control | 2022-03-01 |
| PRECLINICAL | evidence | Clinical review of subcutaneous semaglutide for obesity. | Wegovy | Weight & fat loss | 2022-02-01 |
| PRECLINICAL | evidence | Wegovy (semaglutide): a new weight loss drug for chronic weight management. | Wegovy | — | 2022-01-01 |
| PRECLINICAL | evidence | Development and approval of rybelsus (oral semaglutide): ushering in a new era in peptide delivery. | Rybelsus | Glycemic control | 2022-01-01 |
| PRECLINICAL | evidence | [Oral semaglutide - Rybelsus(R), the first GLP-1 receptor agonist for oral use in clinical practice]. | Rybelsus | Glycemic control | 2022-01-01 |
| PRECLINICAL | evidence | [New drug for type 2 diabetes: introduction of oral Semaglutide (Rybelsus((R)) tablets), an oral GLP-1 receptor agonist]. | Ozempic | Glycemic control | 2022-01-01 |
| PRECLINICAL | evidence | Semaglutide (Wegovy) for weight loss. | Wegovy | — | 2021-07-12 |
| PRECLINICAL | evidence | A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes. | Rybelsus | Glycemic control | 2021-06-01 |
| PRECLINICAL | evidence | Semaglutide (Ozempic) for weight loss. | Ozempic | Weight & fat loss | 2021-04-05 |
| PRECLINICAL | evidence | Oral Semaglutide (Rybelsus) for the Treatment of Type 2 Diabetes Mellitus. | Rybelsus | Glycemic control | 2020-11-15 |
| PRECLINICAL | evidence | Semaglutide Is a New Once-Daily Oral Medication to Treat Type 2 Diabetes. | Rybelsus | Glycemic control | 2020-10-01 |
| PRECLINICAL | evidence | [Not Available]. | Rybelsus | — | 2020-08-01 |
| PRECLINICAL | evidence | Oral semaglutide in type 2 diabetes. | Rybelsus | Glycemic control | 2020-04-01 |
| PRECLINICAL | evidence | Drugs for type 2 diabetes. | Ozempic | Glycemic control | 2019-11-04 |